Brief: Eagle Pharmaceuticals On Track To Support Submission Of New Drug Application In Q2 2022 For Landiolol
31/01/2022 11:55
Jan 31 (Reuters) -
* EAGLE PHARMACEUTICALS ON TRACK TO SUPPORT SUBMISSION OF
NEW DRUG
APPLICATION IN SECOND QUARTER 2022 FOR LANDIOLOL, A BETA-1
ADRENERGIC BLOCKER
* EAGLE - AOP HEALTH ENGAGED WITH FDA TO OBTAIN ALIGNMENT ON
PRE-CLINICAL AND CLINICAL DATA REQUIRED TO SUPPORT NDA SEEKING
APPROVAL OF LANDIOLOL
* EAGLE PHARMACEUTICALS INC - BASED ON FDA'S RESPONSES TO
AOP
HEALTH'S COMMUNICATIONS, WE REMAIN ON TRACK TO SUPPORT NDA NEXT
QUARTER
Source text for Eikon: ID:nBw8f72xra
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eagle Pharmaceuticals
See all newsDoes a common heart attack pill help everyone? Studies disagree
Brief: Eagle Pharmaceuticals Says Continuing To Evaluate Its Internal Control Over Financial Reporting
Brief: Nantahala Capital Management, Llc Reports 15.1% Passive Stake In Eagle Pharmaceuticals Inc As Of June 30- SEC Filing
Brief: Eagle Pharmaceuticals Says On May 28, Co Requested Hearing Before Hearings Panel Of Nasdaq, Following Delisting Notice From Nasdaq - SEC Filing
Brief: Eagle Pharmaceuticals Announces Receipt Of Delisting Notification From Nasdaq